Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering on possible TRA partners

Executive Summary

Talks with pharmaceutical companies about a potential collaboration on its Phase III thrombin receptor antagonist for atherothrombosis have reached a stumbling block because potential partners have no comparably valuable asset to offer in return, CEO Fred Hassan said during the Morgan Stanley CEOs Unplugged conference Jan. 3. The firm is apparently looking for a quid pro quo relationship: "We are asking them to show us a quid that has the same kind of value so that we can diversify on both sides, and unfortunately for the larger companies they have nothing to show us. That is the biggest challenge," he said. Schering has "talked to practically all the big companies" and remains open to further discussions, he added. Schering announced its interest in partnering on TRA several months ago 1("The Pink Sheet" Oct. 29, 2007, p. 5)...

You may also be interested in...



Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO

The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.

FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.

Stada Names New Global Development Head

Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel